11月21日，威高骨科跌3.62%，成交额4814.93万元。两融数据显示，当日威高骨科获融资买入额914.95 万元，融资偿还1583.36万元，融资净买入-668.41万元。截至11月21日，威高骨科融资融券余额合计 1.42亿元。 融资方面，威高骨科当日融资买入914.95万元。当前融资余额1.42亿元，占流通市值的1.25%，融资余 额超过近一年80%分位水平，处于高位。 融券方面，威高骨科11月21日融券偿还0.00股，融券卖出300.00股，按当日收盘价计算，卖出金额 8541.00元；融券余量5351.00股，融券余额15.23万元，超过近一年80%分位水平，处于高位。 责任编辑：小浪快报 资料显示，山东威高骨科材料股份有限公司位于山东省威海市旅游度假区香江街26号，成立日期2005年 4月6日，上市日期2021年6月30日，公司主营业务涉及骨科医疗器械的研发、生产和销售。主营业务收 入构成为：关节29.01%，脊柱28.99%，运动医学和组织修复19.11%，创伤16.64%，其他6.10%，其他 (补充)0.15%。 截至9月30日，威高骨科股东户数1.07万，较上期增加18.33%；人均流 ...

资料显示，山东威高骨科材料股份有限公司位于山东省威海市旅游度假区香江街26号，成立日期2005年 4月6日，上市日期2021年6月30日，公司主营业务涉及骨科医疗器械的研发、生产和销售。主营业务收 入构成为：关节29.01%，脊柱28.99%，运动医学和组织修复19.11%，创伤16.64%，其他6.10%，其他 (补充)0.15%。 截至9月30日，威高骨科股东户数1.07万，较上期增加18.33%；人均流通股37418股，较上期减少 15.49%。2025年1月-9月，威高骨科实现营业收入11.06亿元，同比增长2.12%；归母净利润2.07亿元，同 比增长26.24%。 11月14日，威高骨科涨1.24%，成交额7193.21万元。两融数据显示，当日威高骨科获融资买入额 1425.66万元，融资偿还1278.37万元，融资净买入147.29万元。截至11月14日，威高骨科融资融券余额 合计1.50亿元。 融资方面，威高骨科当日融资买入1425.66万元。当前融资余额1.49亿元，占流通市值的1.20%，融资余 额超过近一年90%分位水平，处于高位。 融券方面，威高骨科11月14日融券偿还0.00股，融券 ...

Core Insights - The company reported a revenue of 1.106 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 2.12% [1] - The net profit attributable to shareholders was 207 million yuan, showing a significant increase of 26.24% year-on-year [1] - The basic earnings per share (EPS) for the reporting period was 0.52 yuan [1] Financial Performance - The gross profit margin for Q3 2025 was 60.80%, a decrease of 5.21 percentage points year-on-year and a decline of 7.52 percentage points quarter-on-quarter [1] - The net profit margin for Q3 was 18.21%, down 3.50 percentage points compared to the same period last year and down 2.22 percentage points from the previous quarter [1] - Total operating expenses for Q3 were 456 million yuan, a decrease of 58.12 million yuan year-on-year, with an expense ratio of 41.22%, down 6.24 percentage points year-on-year [1] Shareholder Information - As of the end of Q3 2025, the total number of shareholders was 10,700, an increase of 1,656 shareholders or 18.33% from the end of the previous half [2] - The average market value per shareholder increased from 1.1862 million yuan to 1.2311 million yuan, a growth of 3.78% [2] Business Overview - The company specializes in the research, production, and sales of orthopedic medical devices, with its main revenue sources being joint products (29.01%), spine products (28.99%), sports medicine and tissue repair (19.11%), trauma products (16.64%), and others (6.10%) [2] - The company is classified under the pharmaceutical and biological industry, specifically in medical devices and consumables [2]

Core Viewpoint - Weigao Orthopedics has shown a mixed financial performance with a slight decrease in revenue but a significant increase in net profit, indicating potential resilience in profitability despite revenue challenges [2]. Financing Summary - On October 9, Weigao Orthopedics experienced a financing buy-in of 19.40 million yuan, with a net buy of 11.10 million yuan, reflecting strong investor interest [1]. - The total financing and securities balance reached 147 million yuan, accounting for 1.11% of the circulating market value, which is above the 90th percentile of the past year, indicating a high level of financing activity [1]. - The short-selling activity was low, with no shares repaid and only 700 shares sold, resulting in a short-selling balance of 6.62 thousand yuan, below the 40th percentile of the past year [1]. Financial Performance - For the first half of 2025, Weigao Orthopedics reported a revenue of 741 million yuan, a year-on-year decrease of 1.28%, while the net profit attributable to shareholders increased by 52.43% to 142 million yuan [2]. - Cumulatively, the company has distributed 535 million yuan in dividends since its A-share listing, with 327 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 1.46% to 9,034, while the average circulating shares per person decreased by 1.44% to 44,277 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 3.05 million shares, a decrease of 746,300 shares compared to the previous period [3].